Annexin A1 attenuates cardiac diastolic dysfunction in mice with inflammatory arthritis. by Chen, J et al.
Annexin A1 attenuates cardiac diastolic dysfunction in
mice with inflammatory arthritis
Jianmin Chena,1,2, Lucy V. Norlinga,1, Jose Garrido Mesaa, Marina De Paula Silvaa, Sophie E. Burtona,
Chris Reutelingspergerb, Mauro Perrettia,3, and Dianne Coopera,2,3
aWilliam Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, United
Kingdom; and bDepartment of Biochemistry, Cardiovascular Research Institute, Maastricht University, Maastricht 6229HX, The Netherlands
Edited by Ruslan Medzhitov, Yale University, New Haven, CT, and approved August 11, 2021 (received for review September 29, 2020)
Rheumatoid arthritis (RA) carries a twofold increased incidence of
heart failure with preserved ejection fraction, accompanied by
diastolic dysfunction, which can lead to death. The causes of
diastolic dysfunction are unknown, and there are currently no well-
characterized animal models for studying these mechanisms. Current
medications for RA do not have marked beneficial cardio-protective
effects. K/BxN F1 progeny and KRN control mice were analyzed over
time for arthritis development, monitoring left ventricular diastolic
and systolic function using echocardiography. Excised hearts were
analyzed by flow cytometry, qPCR, and histology. In pharmacological
experiments, K/BxN F1 mice were treated with human recombinant
AnxA1 (hrAnxA1, 1 μg/mouse) or vehicle daily. K/BxN F1 mice
exhibited fully developed arthritis with normal cardiac function at
4 wk; however, by week 8, all mice displayed left ventricular diastolic
dysfunction with preserved ejection fraction. This dysfunction was
associated with cardiac hypertrophy, myocardial inflammation and
fibrosis, and inflammatory markers. Daily treatment of K/BxN F1
mice with hrAnxA1 from weeks 4 to 8 halted progression of the
diastolic dysfunction. The treatment reduced cardiac transcripts of
proinflammatory cytokines and profibrotic markers. At the cellular
level, hrAnxA1 decreased activated T cells and increased MHC IIlow
macrophage infiltration in K/BxN F1 hearts. Similar effects were
obtained when hrAnxA1 was administered from week 8 to week
15. We describe an animal model of inflammatory arthritis that
recapitulates the cardiomyopathy of RA. Treatment with hrAnxA1
after disease onset corrected the diastolic dysfunction through
modulation of both fibroblast and inflammatory cell phenotype
within the heart.
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Rheumatoid arthritis (RA) is a chronic inflammatory conditionof the joints that causes pain, reduced mobility, and impaired
quality of life. While the joint disease per se is not lethal, around
half of all premature deaths in RA patients are due to cardiovas-
cular comorbidities (1, 2), among which nonischemic heart failure
plays a predominant role (3–5), although the pathogenesis of
nonischemic heart failure may include undetected coronary artery
disease (6). The incidence of congestive heart failure (CHF) in
patients with RA is approximately twofold higher than the general
population (7). RA patients are particularly susceptible to heart
failure with preserved ejection fraction (HFpEF), which is ac-
companied by a diastolic dysfunction with normal or near normal
EF (8). Even without clinical evidence of heart malfunction,
around 40% of RA patients present asymptomatic left ventricular
(LV) diastolic dysfunction with or without preserved systolic
function. This diastolic dysfunction, if progressive over time, con-
tributes to CHF (9). While 80% of CHF in the general population
is attributed to traditional risk factors (hyperlipidemia, diabetes,
and hypertension), in RA these factors are linked to only 40% of
CHF incidence (10). Therefore, there are unexplained risk fac-
tor(s) for CHF in RA patients likely related to systemic and local
inflammation; however, these mechanism(s) remain by and large
elusive. Moreover, limited beneficial cardio-protective effects have
been observed for medications currently used in RA treatment,
while in some cases, deterioration has been reported (5): the
clinical unmet need for increased CHF in RA remains pressing.
While acute inflammation is a protective reaction to invading
pathogens or tissue damage, this protection is ideally contained
in time and space. When inflammation is prolonged, it can expand
from the primary tissue to secondary sites resulting in development/
exacerbation of comorbidities like the enhanced cardiovascular
disease observed in RA patients (11). Physiological inflammation
actively resolves, governed by endogenous mediators signaling
through G protein-coupled receptors (GPCRs), including ALX/
FPR2. In fact, the formyl-peptide receptor (FPR) family of GPCRs
plays an important role in host defense, regulation of inflammation,
and its resolution (12). Particularly, FPR2 facilitates resolution of
inflammation in experimental inflammatory arthritis upon activa-
tion by annexin A1 (AnxA1) (13) and resolvin D1 (14). Equally
importantly, FPR2 agonists such as AnxA1 (15), resolvin D1 (16),
and lipoxin A4 (17) are cardio protective in experimental settings of
myocardial infarction. FPRs might therefore represent a therapeutic
target for the cardiomyopathy associated with inflammatory arthritis.
To start elucidating mechanisms and potential therapeutic strat-
egies, we have characterized cardiac function in a mouse model of
arthritis, the K/BxN F1 progeny, recapitulating the diastolic dysfunction
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reported in RA patients. These mice express both the T cell receptor
transgene KRN and themajor histocompatibility complex (MHC) class
II molecule Ag7 from the NOD/ShiLtJ mouse strain leading to the
development of arthritis spontaneously (18). Having established this
clinically relevant model of diastolic dysfunction associated with
arthritis, we then investigated the potential beneficial effects of
human recombinant AnxA1 (hrAnxA1) against the diastolic dys-
function of K/BxN F1 mice.
Results
Arthritic Mice Develop Diastolic Dysfunction with Preserved EF. In
our quest for a model of inflammatory arthritis which could display
HFpEF and diastolic cardiomyopathy, we tested the F1 progeny of
the KRN mice coupled to the NOD colony (18). In initial exper-
iments, ankle swelling first became visible from week 3 and pla-
teaued from week 4 with near maximal clinical score (Fig. 1A).
Control KRN mice did not show any indication of arthritis. There
was a nonsignificant trend of reduced body weight in K/BxN F1
mice compared to KRN mice from 10 wk onwards (Fig. 1A). The
same groups were followed for the development of cardiac dys-
function using echocardiography. When compared with KRN
mice, enlargement of left atrial (LA) area, one of the most sensi-
tive markers for diastolic dysfunction (19), was first detectable in
half of K/BxN F1 mice at week 6 (Fig. 1B). By week 8, all K/BxN
F1 mice showed enlarged LA area, reduced E/A ratio, reduced E
wave, and increased deceleration time (Fig. 1 B and C), indicating
full development of diastolic dysfunction. Enlargement of LA area
and increased deceleration time deteriorated further over time and
were monitored until week 15 (Fig. 1 B and C). It is noteworthy
that EF, as an indicator of systolic function, was preserved in
K/BxN F1 mice throughout the entire time-course (Fig. 1D).
In line with previous work (20), we observed a degree of mitral
valve inflammation in 15-wk-old K/BxN F1 mice, indicated by
thickened mitral valve leaflets (SI Appendix, Fig. S1). Functional
analysis of the mitral valve using color Doppler showed that only
two out of 10 15-wk-old K/BxN F1 mice developed trivial mitral
regurgitation, indicated by a blue jet area in LA as the mitral
valve closes at the early stage of systolic phase (Video S1), while
the rest of K/BxN F1 mice did not show signs of mitral regurgi-
tation (Video S2). Trivial mitral regurgitation was also observed in
age-matched KRN mice (Video S3), indicating that this phe-
nomenon may occur within normal physiological settings. These
findings indicate that the LV diastolic dysfunction in K/BxN F1
mice was not secondary to mitral regurgitation. No obvious mitral
stenosis was observed in 15-wk-old K/BxN F1 mice as indicated by
similar pattern/width of color jet in the LV during diastolic phase
(Video S2) to that observed in age-matched KRN mice (Video
S3). In these mice, we did not observe evidence of pericardial
(Video S4) or pleural fluid accumulation (Video S5), making it
highly unlikely that the LV diastolic dysfunction observed in
K/BxN F1 mice could arise from these phenomena.
Additionally, we observed an increased lung wet to dry weight
ratio in 8-wk-old K/BxN F1 mice compared with age-matched KRN
mice (SI Appendix, Fig. S2A). The same trend was also observed in
15-wk-old K/BxN F1 mice in comparison with age-matched KRN
mice (SI Appendix, Fig. S2B), indicating presence of pulmonary
edema in K/BxN F1 mice. When monitoring physical activity, we
observed that animal movement around the bottom of cage and
rearing were normal in K/BxN F1 mice across different age groups.
No unbalanced gait was seen. Speed of movement was slightly re-
duced in K/BxN F1 mice compared with KRN controls, with a
reduced grip depending on the severity of joint disease. Moreover,
there was no significant difference in mean arterial blood pressure,
systolic pressure, diastolic pressure, or heart rate between
10-wk-old K/BxN F1 mice in comparison with age-matched KRN
controls (SI Appendix, Fig. S2 C–F); the same observation was
obtained in 15-wk-old K/BxN F1 mice in comparison with age-
matched KRN mice (SI Appendix, Fig. S2G–J), indicating that the
LV diastolic dysfunction of arthritic mice, at least at weeks 10 and
15, was not secondary to alterations in blood pressure or heart
rate.
Together, these data showed that arthritic K/BxN F1 mice
developed diastolic dysfunction with preserved EF recapitulating
the dysfunction reported in RA patients. The emergence of
established diastolic dysfunction was 4 wk later than fully de-
veloped arthritis, thus defining two milestones in this mouse
colony: week 4 (mice with arthritis but no diastolic dysfunction)
and week 8 (mice with both arthritis and diastolic dysfunction).
Cardiac Hypertrophy and Fibrosis in Arthritic Mice. To gain mecha-
nistic insights into the pathology of the impaired LV relaxation
of K/BxN F1 mice, we investigated whether these hearts develop
hypertrophy and/or fibrosis, focusing on week 15 at first, when
the disease is fully manifested. When compared with age-matched
KRN mice, there was a significant increase in interventricular
septum thickness in K/BxN F1 mice, but no difference was ob-
served in LV internal diastolic dimensions (Fig. 1E), indicating the
development of concentric hypertrophy of arthritic hearts. Histo-
logical analysis showed that the average diameter of car-
diomyocytes was increased in K/BxN F1 hearts compared with
KRN hearts (Fig. 2A). For fibrosis, we observed higher collagen
deposition in K/BxN F1 hearts compared with KRN (Fig. 2A).
Moreover, galectin-3, which is associated with cardiac fibrosis (21),
was significantly increased (Fig. 2 B and C).
To gain information ahead of established fibrosis, we con-
ducted further analyses at week 8. Both CD45+CD34+Thy1.2+
monocytic-derived fibroblasts (22) and CD45−CD34−Thy1.2+
structural fibroblasts (23) were increased in K/BxN F1 hearts at
8 wk compared with age-matched KRN hearts (SI Appendix, Fig.
S3A and Fig. 2D). VCAM-1, an indicator of proinflammatory
status of fibroblasts (21), was significantly increased in monocytic-
derived fibroblasts in K/BxN F1 hearts (Fig. 2E). Analysis of gene
expression profiles in K/BxN F1 hearts confirmed the changes
described above with higher messenger ribonucleic acid (mRNA)
expression of fibrosis markers including transforming growth fac-
tor beta (Tgfb1) (Fig. 3 A and B) as well as cardiac hypertrophy
markers including β-myosin heavy chain (Myh) and vascular en-
dothelial growth factor (Vegf) (Fig. 3 A and B). No differences in
average diameter of cardiomyocytes or collagen deposition were
detected at 8 wk between KRN and age-matched K/BxN F1 mice
(SI Appendix, Fig. S3 C and D), in line with our echocardiographic
findings that full-blown cardiac hypertrophy is marked at week 15
(Fig. 1E).
Inflammatory Markers Are Modulated in Hearts of Arthritic Mice.
When compared with age-matched KRN hearts, K/BxN F1 hearts
displayed increased mRNA expression of cytokines including Il6,
Il1b, and Il10 at week 8 (Fig. 3 A and B). We also monitored a
selection of proresolving receptors, quantifying higher mRNA ex-
pression for Fpr2. Additionally, the key biosynthetic enzymes of
proresolving lipid mediators, 5- and 15-lipoxygenase, were dysre-
gulated (Alox5 and Alox15), while galectin-1 (Lgals1) gene product
was up-regulated (Fig. 3 A and B). In the kidney, significant dif-
ferences were only detected in MHC-II (H2-ab1), TIM-3 (Havcr2),
and Il1b mRNA as compared to week 8 nonarthritic KRN mice.
These modest changes were unlikely of significance as plasma cre-
atinine levels were not increased even at a later time-point (week
15) in K/BxN F1 mice; rather, they were significantly decreased (SI
Appendix, Fig. S4), probably due to minimal changes in body
weights (Fig. 1A).
Infiltration of Activated T Cells Is Increased in Arthritic Hearts. Next,
we investigated whether cardiac immune cell numbers were al-
tered in these experimental settings (SI Appendix, Fig. S3 B–D).
When compared with age-matched KRN hearts, noninflammatory
CD44−CD62L+ naïve CD4 T cells were decreased in K/BxN F1
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Fig. 1. Arthritic K/BxN F1 mice display diastolic dysfunction but normal systolic function as assessed by echocardiography. (A) K/BxN F1 mice develop marked
arthritis from week 4 with no significant change in body weight. Clinical severity of arthritis was assessed visually using a defined severity scoring system (max
score 12). (B and C) K/BxN F1 mice fully develop diastolic dysfunction from week 8. (B) Representative B-mode four-chamber echocardiograms and increased
LA area in arthritic mice. (C) Representative mitral flow patterns from pulsed-wave color Doppler echocardiography, decreased E/A ratio, decreased E wave
velocity, and increased deceleration time in arthritic mice. (D) K/BxN F1 mice show no significant change in percentages of EF using M-mode echocardiograms.
(E) K/BxN F1 mice develop concentric cardiac hypertrophy at week-15 indicated by an increase in interventricular septum thickness with no difference in LV
internal diastolic dimensions. Data are mean ± SEM. KRN group: n = 5; K/BxN F1 group: n = 6. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 versus
nonarthritic KRN group (two-way ANOVA followed by Bonferroni’s test). K/BxN: K/BxN F1.
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hearts at 8 wk (Fig. 3C), whereas total numbers of activated CD4
T cells, the sum of CD44+CD62L− effector memory, CD44+CD62L+
central memory, and CD44−CD62L− transition status CD4 T cells,
were increased (Fig. 3C). The same pattern emerged for CD8
T cells (Fig. 3D). Week 8 analysis of other immune cell types in-
cluding cardiac CD115+ monocytes, CD11b+Ly6G+ neutrophils,
CD11b+SiglecF+ eosinophils, F4/80+ macrophages, and total
CD4+ and CD8+ T cells in K/BxN F1 hearts revealed no difference
from nonarthritic KRN hearts (SI Appendix, Fig. S5).
Myocardial AnxA1 Does Not Increase over Time in Arthritic Hearts.
Immunostaining for AnxA1 in myocardial sections revealed
no changes in protein expression over time in the K/BxN F1
hearts (SI Appendix, Fig. S6). Intriguingly, the immunostaining
for this proresolving mediator increased over time in nonarthritic
KRNmice, indicating a time-related change possibly linked with aging,
which may be defective in the context of inflammatory arthritis.
hrAnxA1 Treatment (Week 4 to Week 8) Halted Development of
Diastolic Dysfunction in K/BxN F1 mice. In the second part of the
study, we investigated a proof-of-concept intervention on the pa-
thology unveiled here. Having detected that proresolving targets,
particularly FPR2, were up-regulated in the hearts of K/BxN F1
mice, we then tested the potential cardioprotective effects of the
FPR2 agonist hrAnxA1 (24). Daily treatment with this protein
(1 μg/mouse; Fig. 4A) occurred from week 4 (mice with arthritis
but no diastolic dysfunction) and terminated at week 8 (mice with
both arthritis and diastolic dysfunction).
Fig. 2. Arthritic K/BxN F1 mice develop cardiac hypertrophy and fibrosis. (A) Histological and structural analyses in arthritic hearts (week 15). A, i: Macroscopic view of
the arthritic mouse heart stained with hematoxylin–eosin. (Scale bars, 2.5 mm.) A, ii: Representative LV sections stained with hematoxylin–eosin. A, iii: Sirius red from
arthritic and nonarthritic hearts. (Scale bars, 100 μm.) KRN: n = 3; K/BxN F1: n = 6. (B and C) Quantification of galectin-3–positive cells in LV. Representative images are
shown. (Scale bars, 100 μm.) n = 3 to 4 per group. (D) Quantification of fibroblast populations with representative dot plots and (E) VCAM-1 expression for KRN n = 4
and K/BxN F1 n = 5 at week 8. Data are mean ± SEM (A, D, and E ) *P < 0.05, **P < 0.01, ***P < 0.001 versus nonarthritic KRN group (unpaired Student’s
t test); (C) *P < 0.05, **P < 0.01 versus nonarthritic 15-wk-old KRN or 6-wk-old K/BxN F1 group (one-way ANOVA followed by Bonferroni’s test). K/BxN: K/BxN F1.
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When compared with K/BxN F1 mice receiving vehicle,
hrAnxA1 treatment did not impact the clinical signs of arthritis,
such as arthritic scores and body weight loss (SI Appendix, Fig.
S7 A and B). Modest yet significant reductions in arthritic scores
over baseline values (Δ arthritic score) were observed at only two
time-points (day 16 and 18 from start of treatment; SI Appendix,
Fig. S7A). Much more pronounced effects were quantified on
the cardiomyopathy associated with this aggressive arthritis.
When compared with the vehicle group, treatment with
hrAnxA1 significantly attenuated LA area enlargement and the
reduced E/A ratio as early as week 6, that is, 2 wk posttreatment.
These beneficial effects lasted until week 8 (Fig. 4 B–D), indicating
that this pharmacological treatment successfully halted the devel-
opment of the diastolic dysfunction associated with inflammatory
arthritis. No significant alterations in EF, interventricular septum
thickness, or LV internal diastolic dimensions were observed in
hrAnxA1-treated arthritic mice (SI Appendix, Fig. S7 C and D).
To investigate the potential hemodynamic effects of hrAnxA1,
K/BxN F1 mice were treated with hrAnxA1 or vehicle daily from
week 7 to week 8. When compared with K/BxN F1 mice re-
ceiving vehicle, treatment with hrAnxA1 did not impact mean
arterial blood pressure, systolic pressure, diastolic pressure, or
heart rate (SI Appendix, Fig. S7 E–H). Thus, the cardioprotective
effects of hrAnxA1 in K/BxN F1 mice are unlikely to be medi-
ated by modulation of blood pressure or heart rate.
hrAnxA1 (Week 4 to Week 8) Modulates Cellular and Inflammatory
Markers in K/BxN F1 Hearts. Treatment of K/BxN F1 mice with
hrAnxA1 impacted the cellular composition of the myocardium.
Compared to vehicle, a significant reduction in CD45−CD34−Thy1.2+
structural fibroblast numbers was quantified (Fig. 5A), with no
major alterations in CD45+CD34+Thy1.2+ monocytic fibroblasts
(P = 0.19, Fig. 5A). The activation status of both fibroblast types
was attenuated, as indicated by reduced cell surface expression of
VCAM-1 (Fig. 5B).
With respect to cardiac immune cells, hrAnxA1 significantly
reduced both activated CD4 and CD8 T cell numbers, with con-
comitant increases in naïve CD4 and CD8 T cells (Fig. 5 C andD).
A modulation of macrophage phenotype was evident, with higher
counts for F4/80+MHCII− macrophages and no significant change
for F4/80+MHCII+ macrophages (Fig. 5E). No changes in the
proportion of other immune cell types were detected following
4-wk treatment with hrAnxA1 (SI Appendix, Fig. S5).
In terms of mediator expression, hrAnxA1 significantly reduced
cardiac mRNA of proinflammatory cytokines like Il6 and Il1b (Fig.
6A). Similarly, significant reductions were quantified for markers of
fibrosis including Tgfb1, col1a1 (type 1 collagen), Acta2 (α-smooth
muscle actin), and Mmp1a (matrix metalloprotease-1a) (Fig. 6B).
Such a “normalization” of local inflammation was also evident in
relation to the expression of proresolving receptors, mediators and
enzymes (Fig. 6 D–F). Of interest, Fpr2 mRNA expression in the
heart was not altered by hrAnxA1 treatment (Fig. 6C). Congru-
ently, treatment of mice with hrAnxA1 did not alter surface FPR2
expression in blood Ly6G+ neutrophils, Ly6C+ monocytes, or
CD3+ lymphocytes in K/BxN F1 mice (SI Appendix, Fig. S8).
hAnxA1 treatment did not alter mRNA expression of several
markers quantified in K/BxN F1 kidneys (SI Appendix, Fig. S4).
hrAnxA1 (Week 8 to Week 15) Reversed Established Diastolic
Dysfunction and Attenuated Cardiac Remodeling. Next, we applied
a therapeutic protocol with daily hrAnxA1 treatment (1 μg/
mouse) from week 8 (mice with both arthritis and established
diastolic dysfunction) to week 15 (mice with arthritis, diastolic
dysfunction, and cardiac hypertrophy and fibrosis).
When compared with the vehicle group, there was a trend for
LA area reduction by hrAnxA1 treatment (P = 0.06, Fig. 7A). More
strikingly, the E/A ratio was significantly increased by hrAnxA1 as
Fig. 3. Modulated gene signature and increased infiltration of activated T cells in K/BxN F1 arthritic hearts at 8 wk. (A) Ct values of different genes analyzed by
qPCR in K/BxN F1 arthritic hearts at week 8. (B) Differential gene expression in arthritic hearts at week 8. Ct values were normalized using Hprt1 as housekeeping
gene, and fold change was calculated relative to age-matched KRN controls. x-axis shows fold change (in log2 scale), with continued line (X = 1) showing KRN
mean and dotted lines presenting technical variance: ± average SD of replicated PCR measures. y-axis shows the P value (in log10 scale) from t test statistical
analysis, with dotted line at P = 0.05; KRN group: n = 4; K/BxN group: n = 6. (C and D) CD4+ (C) or CD8+ (D) T cells were subdivided into non-proinflammatory
CD44−CD62L+ naïve T cells (Tn), CD44+CD62L− effector memory T cells (Tem), CD44+CD62L+ central memory (Tcm), and CD44−CD62L− transition status (Ttrans).
Data are mean values. KRN group: n = 4; K/BxN F1 group: n = 5. ***P < 0.001 versus nonarthritic KRN group (unpaired Student’s t test). K/BxN: K/BxN F1.
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early as week 10, that is, 2 wk posttreatment initiation. Deceleration
time was significantly shortened by hrAnxA1 from week 13, as
compared with vehicle control. These beneficial effects lasted until
week 15 (Fig. 7 B and C). This treatment at a later stage of the
experimental disease also impacted cardiac remodeling. Week-15
echocardiography analysis showed that interventricular septum
thickness was significantly reduced in the hrAnxA1 group, com-
pared with vehicle (Fig. 7D). This was in line with histological
analyses which demonstrated a decrease in the average diameter of
cardiomyocytes (Fig. 7E). Additionally, when compared with vehi-
cle, hrAnxA1 significantly decreased collagen deposition (Fig. 7E)
and the number of galectin-3–positive cells (Fig. 7F) in K/BxN F1
hearts indicative of a negative impact on disease evolution to more
advanced cardiac remodeling, including cardiac hypertrophy and
fibrosis. A trend, although not significant, for reduction in lung wet
to dry weight ratio was calculated for hrAxA1-treated mice (P =
0.09, Fig. 7G).
Treatment of K/BxN F1 mice with hrAnxA1 at a later stage
modulated both cardiac fibroblast composition and cardiac immune
cells. When compared to vehicle, both CD45+CD34+Thy1.2+
monocytic fibroblasts and CD45−CD34−Thy1.2+ structural fibro-
blasts were reduced by hrAnxA1 (Fig. 8A). The activation marker
of fibroblasts, VCAM-1, was reduced in monocytic fibroblasts
(Fig. 8B), with no major alterations in structural fibroblasts (P =
0.12, Fig. 8B). When compared with the vehicle group, there was a
trend for reduction in activated CD4 T cells, while the naïve CD4
Fig. 4. hrAnxA1 treatment (week 4 to week 8) halts the development of diastolic dysfunction and attenuates cardiac hypertrophy in K/BxN F1 mice. (A)
Schematic indicating treatment and experimental regime. (B) Representative B-mode four-chamber echocardiograms indicating LA area and LA atrial area in
mice treated with hrAnxA1 or vehicle. (C) Representative mitral flow patterns from pulsed-wave color Doppler echocardiography. (D) E/A ratio and decel-
eration time as assessed by echocardiography in arthritic mice treated with hrAnxA1 or vehicle. Data are mean ± SEM. K/BxN F1 + vehicle group: n = 5; K/BxN
F1+ hrAnxA1 group: n = 5. *P < 0.05, **P < 0.01 versus vehicle group (two-way ANOVA followed by Bonferroni’s test). Data are mean ± SEM. K/BxN F1+
vehicle group: n = 4; K/BxN F1 + hrAnxA1 group: n = 5. *P < 0.05 versus vehicle group (unpaired Student’s t test). Veh: vehicle; hAnxA1: hrAnxA1. Echo-
cardiography, flow cytometry, and qPCR were all analyzed blindly.
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T cells were increased by hrAnxA1 treatment (P = 0.06, Fig. 8C).
hAnxA1 significantly reduced activated CD8 T and increased
naïve CD8 T cell numbers in K/BxN F1 hearts (Fig. 8D).
Altogether these data indicate that hrAnxA1 treatment success-
fully reverses the established diastolic dysfunction and associated
cellular changes within the hearts that develop with inflammatory
arthritis.
Discussion
In this study, we characterize a model of HFpEF and concentric
hypertrophy in severe inflammatory arthritis that manifests after
joint disease peaks. Analyses of the hearts of arthritic mice
revealed immune as well as structural insufficiency. A partial
dissociation of the myocardial phenotype from the joint disease
emerges also from the pharmacological studies with hrAnxA1
with modest effects on the arthritic joint but higher efficacy in
correcting the diastolic dysfunction. We propose that the K/BxN
F1 mouse model can be exploited to identify pathways and
therapeutic strategies for the management of the cardiomyopa-
thy that affects RA patients.
In RA patients, diastolic dysfunction is strongly associated
with disease duration (25). In our model, diastolic dysfunction
was established at week 8, 4 wk later than the fully developed
arthritis; this may reflect a chronic myocardial process resulting
Fig. 5. hrAnxA1 treatment (week 4 to week 8) reduces fibroblast populations and activated T cell infiltration and increases MHC IIlow macrophages in the hearts
of K/BxN F1 mice. K/BxN F1 mice were treated with hrAnxA1 [1 μg/mouse daily subcutaneously (s.c.) from week 4 to week 8]. Hearts were enzymatically digested,
and cardiac cell phenotype assessed and quantified by flow cytometry. (A) Representative dot plots showing cardiac monocytic fibroblasts (CD45+CD34+Thy1.2+) and
cardiac structural fibroblasts (CD45−CD34−Thy1.2+) in mice receiving vehicle or hrAnxA1. Cumulative data indicating percentage cardiac monocytic fibroblasts
and cardiac structural fibroblasts in mice treated with vehicle or hrAnxA1. (B) VCAM-1 expression on cardiac fibroblast subtypes. (C and D) Representative dot plots
and cumulative data illustrating CD4 (C) and CD8 (D) noninflammatory CD44−CD62L+ naïve T cells (Tn), CD44+CD62L− effector memory T cells (Tem), CD44+CD62L+
central memory T cells (Tcm), and CD44−CD62L− transition status T cells (Ttrans). (E) Representative dot plots illustrating F/80+MHC IIlow and F/80+MHC IIhigh mac-
rophages K/BxN F1 hearts receiving vehicle or hrAnxA1. Cumulative data indicating total numbers of F/80+MHC IIlow and F/80+MHC IIhigh macrophages. n = 4 to 5 per
group. All data are mean ± SEM *P < 0.05, ***P < 0.001 versus K/BxN F1+ vehicle group (unpaired Student’s t test). Veh: vehicle; hAnxA1: hrAnxA1.
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in impairment of cardiac function. At week 8, the development
of diastolic dysfunction in K/BxN F1 mice was confirmed by an
enlarged LA area (suggestive of reduced LV compliance), re-
duced E/A ratio, reduced E wave, and increased deceleration
time; these dynamic changes are essentially the same as reported
in RA patients (9). The normal renal function detected in K/BxN
F1 mice indicates that the cardiac dysfunction was not secondary
to cardiorenal syndrome. Additionally, no differences in blood
pressure were observed between K/BxN F1 arthritic mice and
KRN control mice at week10, 15, or vehicle-treated mice at 8 wk.
This outcome is in line with previous studies in rodents with
collagen-induced arthritis which showed that blood pressure
values were not altered by the disease (26, 27). Increased blood
pressure is a common comorbidity in HFpEF patients and is a
contributory pathogenic factor in some patients with diastolic
dysfunction (28, 29). Furthermore, clinical evidence has shown
that the prevalence of hypertension increases with age and dis-
ease duration in patients with RA (30). It is therefore likely that
hypertension is a comorbidity that contributes to development of
diastolic dysfunction in some RA patients. However, in this
murine model of diastolic dysfunction in K/BxN F1 mice, our
data points to systemic inflammation rather than modulation of
blood pressure as the major driving force for the observed car-
diac phenotype. While we have not ruled out hypertension in
K/BxN F1 mice younger than 8 wk of age, we speculate that it is
unlikely that these mice would be hypertensive at weeks 4
through 6 then become normotensive at week 8 onwards after
developing diastolic dysfunction. We propose that alterations in
systemic blood pressure are not causative of diastolic dysfunction
in arthritic mice, at least in the conditions investigated here.
The clinical impact of HFpEF in RA has prompted some in-
vestigation into cardiac function in murine models of arthritis. In
a recent study (31), cardiac dysfunction in collagen antibody-
induced arthritis was reported; these mice developed a systolic
alteration, not a diastolic one as reported here and, relevantly,
characterized in RA patients. Nonetheless, this important study
showed mice with collagen antibody-induced arthritis developed
cardiac hypertrophy and fibrosis and isolated cardiomyocytes
from these mice displayed impaired Ca2+ signaling. In a separate
study (32), Zhou et al. reported susceptibility to cardiac systolic
dysfunction and dilated cardiomyopathy in mice undergoing an
experimental arthritis induced with collagen antibody. Finally,
we note how the K/BxN F1 progeny have been used in a single
study to investigate secondary organ injury: these authors ob-
served the spontaneous development of endocarditis by week 8.
Interestingly, while the arthritic phenotype of K/BxN mice is
dependent on complement C5, such a pathway was not required
for the development of endocarditis, which relied on FcγR, the
absence of which had little impact on arthritis severity (20).
In non-RA settings, the pathology of HFpEF is linked to im-
mune dysregulation and systemic inflammation (28). This results
in cardiac remodeling leading to functional changes character-
ized by LV hypertrophy, fibrosis, and diastolic dysfunction (28).
In RA patients, the cardiomyopathy correlates with LV con-
centric hypertrophy characterized by LV wall thickening without
dilation, contributing to diastolic dysfunction and HFpEF (33).
These features could be demonstrated in K/BxN F1 mice, which
at week 15 develop concentric hypertrophy of the heart (20).
Such a macroscopic and significant sign of pathology may plau-
sibly result from molecular changes that occur as early as week 8,
as indicated by up-regulated mRNA expression of cardiac hy-
pertrophy markers like β-myosin heavy chain and VEGF.
In RA patients, myocardial fibrosis and inflammation detected
by cardiac magnetic resonance imaging are evident even in a
proportion of patients with no overt cardiovascular diseases (34),
and it is not surprising that the detected cardiac fibrosis and in-
flammation are associated with the development of CHF (35). In
our study, we have quantified an up-regulation of cardiac proin-
flammatory cytokines in K/BxN F1 mice; this could be the result of
a 1) direct impact of systemic inflammation (e.g., higher circulating
cytokines) (28) and/or 2) local inflammation provoked by interac-
tion of glucose-6-phosphate isomerase autoantibodies activating Fc
Fig. 6. Impact of hrAnxA1 treatment (week 4 to week 8) on cardiac gene expression in K/BxN F1 mice. mRNA expression of (A) Proinflammatory cytokines: Il6
and Il1b; (B) Cardiac fibrosis markers: Tgfb, Col1a1, Acta, and Mmp1a; (C) AnxA1 receptor: Fpr2; (D) Melanocortin receptor 1: Mc1r; (E) 15-lipoxygenase:
Alox15; and (F) Galectin-1: Lgals1; Galectin-3: Lgals3; TIM-3 (receptor of Galectin-9): Havcr2. Ct values were normalized using Hprt1 as housekeeping gene.
Data are mean ± SEM. KRN group: n = 4; K/BxN F1 + vehicle group: n = 6; K/BxN F1 + hrAnxA1 group: n = 6. Fold change was calculated relative to age-
matched nonarthritic KRN controls (mean value = 1), with dotted line showing technical variance indicated by ± average SD of replicated PCR measures for
each gene. *P < 0.05, **P < 0.01, ***P < 0.001 versus vehicle group (unpaired Student’s t test).
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receptors (20). In parallel, collagen accumulation was increased in
these hearts indicating presence of fibrosis, possibly the end-point
of 1) elevated numbers of both cardiac monocytic and structural
fibroblasts and 2) their increased activity indicated by elevated
Tgfb1 mRNA and VCAM-1 protein expression. In line with our
findings, increased monocytic fibroblasts derived from the bone
marrow can mediate cardiac fibrosis in a model of angiotensin II-
induced cardiac hypertrophy (22). Up-regulation of adhesion
molecules on cardiac fibroblasts plays a key role in recruitment and
infiltration of immune cells which contributes to heart inflamma-
tory disorders including CHF (36). The increased surface expres-
sion of VCAM-1 in cardiac fibroblasts might be secondary to up-
regulated cardiac proinflammatory cytokines (36) in the arthritic
mice. Increased VCAM-1, in turn, may have promoted recruitment
of activated T cells through VCAM-1/α4β1 integrin interaction
(37), forming a feed-forward mechanism and amplifying the in-
flammatory reaction within arthritic hearts. The link between
T cells and diastolic dysfunction or HFpEF has not been fully
Fig. 7. hrAnxA1 treatment (week 8 to week 15) reverses the established diastolic dysfunction and attenuates cardiac remodeling in K/BxN F1 mice. K/BxN F1
mice were treated with either hrAnxA1 (1 μg/mouse, daily subcutaneous injection from week 8 to week 15) or vehicle (100 μL saline). Echocardiography was
performed in K/BxN F1 at 8 wk (baseline) before hrAnxA1 or saline administration and at 10, 13, and 15 wk. (A) Representative B-mode four-chamber
echocardiograms indicating LA area and cumulative data of LA area in mice treated with hrAnxA1 or vehicle. (B) Representative mitral flow patterns from
pulsed-wave color Doppler echocardiography. (C) E/A ratio and deceleration time as assessed by echocardiography in arthritic mice treated with hrAnxA1 or
vehicle. (D) hrAnxA1 reduced interventricular septum thickness in arthritic mice at 15 wk. Data are mean ± SEM. K/BxN F1 + vehicle group: n = 6; K/BxN F1+
hrAnxA1 group: n = 6. *P < 0.05, ***P < 0.001 versus vehicle group (two-way ANOVA followed by Bonferroni’s test). (E) Representative LV sections stained
with hematoxylin–eosin and Sirius red from arthritic hearts received hrAnxA1 or vehicle and respective cumulative data. (Scale bars, 100 μm.) (F) Quantifi-
cation of galectin-3–positive cells in LV. Representative images are also shown. (Scale bars, 100 μm.) (G) Lung wet-to-dry weight ratio. *P < 0.05, **P < 0.01,
and ***P < 0.001 versus vehicle group (unpaired Student’s t test). Veh: vehicle; hAnxA1: hrAnxA1.
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elucidated. We report here an increased proportion of activated
T cells associated with and potentially contributory to the devel-
opment of diastolic dysfunction. Other studies suggest that acti-
vated T cells play a pivotal role in nonischemic, pressure
overload–induced cardiomyopathy as well as in rejection of heart
allografts, as activated T cell infiltration into the LV predisposes
LV inflammation, hypertrophy, fibrosis, and systolic dysfunction;
this is likely to be of functional relevance because T cell inhibition
or deficiency alleviated these pathological changes (38–40).
Having characterized at least some elements of this model of
HFpEF in KBxN F1 mice, the second part of the study was di-
rected to use it as proof-of-concept for therapeutic investigation.
Since persistent inflammation leading to fibrosis may be due not
only to excessive proinflammatory mediators but also to defects
in endogenous proresolving mechanisms (11), we monitored
specific effectors of resolution including galectin-1, FPR2, and 5-
and 15-lipoxygenase (11). We focused on FPR2–up-regulated in
the arthritic mice, because this receptor is emerging as a target for
cardio protection with an on-going Phase I trial for a small mol-
ecule agonist (ClinicalTrials.gov Identifier: NCT03335553) (41).
Moreover, an FPR1/FPR2 dual agonist, compound 17b, preserves
cardiac function in models of acute myocardial infarction (42),
while another dual agonist, compound 43, affords cardio protec-
tion in experimental heart failure induced by permanent coronary
artery ligation through its ability to modify macrophage phenotype
(43). We have a long-dated interest in FPRs and their agonist
AnxA1; the heart can be targeted by AnxA1 and AnxA1 peptide
Ac2-26 protecting against myocardial ischemia reperfusion injury
(15, 44). These cardio-protective effects are mediated by FPR2 as
demonstrated by loss of efficacy after administration of receptor
antagonists (44) and persistence of efficacy in FPR1 null mice
(45). More recently, hrAnxA1 was showed to protect against
myocardial inflammation in type I diabetes–induced cardiomy-
opathy, a result obtained through dampening cardiac MAPK sig-
naling and activating the prosurvival Akt pathway (24).
Based on this background and due to the translational potential
inherent of this receptor target, we tested the effect of daily ad-
ministration of hrAnxA1 in arthritic K/BxN F1 mice observing a
remarkable attenuation of the diastolic cardiomyopathy. It is dif-
ficult to tease out the site of action; the fact that the aggressive
arthritis of the joint was only minimally affected by the treatment
suggests that cardio protection may occur independently from any
amelioration of joint disease. Rather, it could derive from effects
downstream of changes in the circulation or the heart itself.
The role of AnxA1 in experimental arthritis has been reported
with different outcomes depending on the model and the route
of administration. In the collagen-induced arthritis model, ad-
ministration of hrAnxA1 during the immune phase augmented
the severity of arthritis in the effector phase, probably through a
positive action on the T cell response (46). Contrasting data have
been reported though (47), and this discrepancy has been dis-
cussed (48) but to our knowledge not solved. It may lie on the fine
regulation of the interaction between dendritic cells and T cells.
Our experience with the serum-transfer model of arthritis did not
highlight powerful inhibitory properties of hrAnxA1 on joint in-
flammation, but 1) a cleavage-resistant AnxA1 was effective in
attenuating joint disease, and 2) dexamethasone lost most of its
efficacy in AnxA1 null mice (49). In summary, the pharmacolog-
ical properties of AnxA1 vary across models and experimental
protocols. In the model of K/BxN F1 arthritis used here, we reason
Fig. 8. hrAnxA1 treatment (week 8 to week 15) reduces fibroblast populations and activated T cell infiltration in the hearts of K/BxN F1 mice. K/BxN F1 mice
were treated with either hrAnxA1 (1 μg/mouse, daily subcutaneous injection from week 8 to week 15) or vehicle (100 μL saline). Hearts were enzymatically
digested, and cardiac cell phenotype assessed and quantified by flow cytometry. (A) Representative dot plots showing cardiac monocytic fibroblasts
(CD45+CD34+Thy1.2+) and cardiac structural fibroblasts (CD45−CD34−Thy1.2+) in mice receiving vehicle or hrAnxA1. Cumulative data indicating percentage
cardiac monocytic fibroblasts and cardiac structural fibroblasts in mice treated with vehicle or hrAnxA1. (B) VCAM-1 expression on cardiac fibroblast subtypes.
(C and D) Representative dot plots and cumulative data illustrating CD4 (C) and CD8 (D) noninflammatory CD44−CD62L+ naïve T cells (Tn), CD44+CD62L−
effector memory T cells (Tem), CD44+CD62L+ central memory T cells (Tcm), and CD44−CD62L− transition status T cells (Ttrans). n = 6 per group. All data are
mean ± SEM. *P < 0.05, **P < 0.01 versus K/BxN F1+ vehicle group (unpaired Student’s t test). Veh: vehicle; hAnxA1: hrAnxA1.
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that the high severity of the joint disease precluded the possibility
to unveil direct anti-arthritic effects of hrAnxA1.
A different scenario emerged at the level of the heart. Treat-
ment of mice with hrAnxA1 drastically reduced proinflammatory
cytokine transcripts including IL-6 and IL-1β. Moreover, the
treatment impacted on cellular events selectively. Myocardial in-
flammation and fibrosis are associated with the development of
CHF in RA patients (35). In these experiments, hrAnxA1 reduced
fibroblast populations and profibrotic markers. The reduced fi-
broblast surface expression of VCAM-1 could be the consequence
of both an indirect effect of hrAnxA1 through reduced inflam-
mation (36) and a direct action on the cell. FPR2 is expressed in
cardiac fibroblasts (50) as well as lung and renal fibroblasts (51,
52). In lung fibroblasts, AnxA1 mimetics regulate TNF-induced
proliferation and inflammatory responses in an FPR2-dependent
manner (51). Additionally, overexpression of AnxA1 attenuates
profibrotic activity of TGF-β-treated renal fibroblasts (52). In our
settings, the reduced myocardial inflammation may decrease sur-
face expression of VCAM-1 in cardiac fibroblasts (36), which in
turn reduces activated T cell recruitment (37), promoting in this
manner a therapeutic feed-forward circuit that further dampens
myocardial inflammation upon AnxA1 treatment in K/BxN F1
mice. Additionally, FPR activation by compound 43 inhibits the
expansion of activated CD4 T cells in murine models of inflam-
matory arthritis (53), which at least in part might explain the re-
duced infiltration of activated T cells in K/BxN F1 hearts after
treatment with hrAnxA1.
Moreover, hrAnxA1 increased cardiac MHC IIlow macrophages
in K/BxN hearts. FPR2 is highly expressed in macrophages (12);
therefore, the shift toward MHC IIlow macrophages upon
hrAnxA1 treatment may be due to direct action on this cell type.
In settings of muscle injury, hrAnxA1 favors tissue repair by
controlling macrophage phenotype switch, an effect downstream
of FPR2 activation and associated with AMPK activation (54).
The same study revealed how human monocyte-derived macro-
phages express high levels of FPR2 when polarized to an inflam-
matory phenotype, with much lower expression of the receptor
protein and gene transcript, when polarized toward a reparative
macrophage. In other words, FPR2 can act as a switch for mac-
rophage reactivity and sensor of the tissue environment. Within
cardiac tissue, macrophage subsets are defined on expression of
MHC II and CCR2 supported by both transcriptional and func-
tional analysis as well as a single-cell RNA-sequencing study (55,
56). MHC IIlow macrophages display higher protease and matrix
metalloprotease activity which enhances matrix breakdown,
whereas MHC IIhigh macrophages are enriched for a gene set that
regulates profibrotic TGF-β and promote fibrosis (57). In line with
our findings, increased MHC IIlow macrophages are associated with
improved diastolic dysfunction induced by hypertension in mice
(57). Of relevance, in settings of myocardial infarction, hrAnxA1
afforded cardio protection by promoting local angiogenesis through
polarization of a specific macrophage subtype (58). This seems to be
different from what is observed here, though more focused analyses
may be required. Therefore, as for the fibroblasts and irrespective of
whether a direct or indirect effect of hrAnxA1 regulates macro-
phage phenotype, these cellular events and the fine-tuning of their
activation status can chiefly contribute to the protection afforded by
this mediator against the diastolic cardiomyopathy.
Treatment with hrAnxA1 from week 8 to week 15 not only
successfully reversed the established diastolic dysfunction asso-
ciated with inflammatory arthritis but also attenuated cardiac
hypertrophy and fibrosis. These protective effects were, at least
in part, contributed by the reduction in count and the activation
status of cardiac fibroblasts and cardiac immune cells.
It is noteworthy that prolonged treatment with hrAnxA1 did not
affect expression of FPR2 on circulating white blood cells. This
result is aligned with the lack of reduction in heart Fpr2 mRNA
expression even when the diastolic dysfunction was significantly
corrected (suggesting that elevated cardiac Fpr2 mRNA was not
contributing to the heart inflammation and fibrosis but possibly
part of a frustrated circuit aiming to dampen these pathological
events). Altogether, these observations may have bearing on
the development of AnxA1 mimetics or FPR2 small-molecule
agonists, suggesting that repeated treatment with the proper
frequency and dosage should not lead to receptor down-
regulation and desensitization. Clearly, this needs to be sub-
stantiated by future experiments.
The complex nature of inflammatory arthritis and its second-
ary injury to other organs (the heart under focus here, but also,
lungs and kidneys can be affected in chronic settings) is more
complex than simply due to a “sustained inflammatory phase.”
We propose that a modulation of the host inflammatory re-
sponse rather than inhibiting inflammation through classic anti-
inflammatories could yield better therapeutic outcomes. Instead
of merely inhibiting inflammation, resolution of inflammation is
characterized in multiple effects on immune and stromal cells
through downstream positive/activating mechanisms (11). In the
settings of nonresolving chronic inflammatory arthritis presented
here, hrAnxA1 not only reduced proinflammatory cytokines and
profibrotic markers in the heart but also decreased activated
cardiac T cells and induced a macrophage–phenotype switch
which may explain why this therapeutic approach can have an
advantage over classic anti-inflammatories.
In conclusion, we have characterized a mouse model of in-
flammatory arthritis, K/BxN F1 progeny, in which the specific
diastolic dysfunction with preserved EF typical of RA patients is
recapitulated. This diastolic dysfunction is associated with cardiac
hypertrophy and myocardial inflammation and fibrosis. Maintained
expression of a specific proresolving receptor in the diseased hearts
prompted us to test administration of hrAnxA1. Indeed, hrAnxA1
halted the progression of cardiac diastolic dysfunction in KBxN
F1 mice without substantial modulation of the clinical severity of
arthritis. Therefore, we envisage a cotherapy approach to halt
aggressive arthritis and prevent cardiomyopathy. The cardio protec-
tion exerted by hrAnxA1 in these mice is associated with 1) reduced
cardiac fibroblast populations and profibrotic markers; 2) modulated
cardiac immune cells including decreased activated T cell infiltration
and increased MHC IIlow macrophages; and 3) down-regulated
proinflammatory cytokines. Thus, we propose that hrAnxA1 and/or
FPR2 agonists, as prototypical exemplars of resolution pharmacology,
may offer an approach to the treatment of diastolic dysfunction or
HFpEF associated with inflammatory arthritis.
Materials and Methods
Additional details on the methods are provided in SI Appendix.
Animals. All animal procedures were performed in accordance with the in-
stitutional Animal Welfare Ethical Review Body and UK Home Office
guidelines. Details of the colonies used and animal welfare are available in
SI Appendix.
Assessment of LV Diastolic and Systolic Function In Vivo. M-mode and Doppler
echocardiography were performed using a Vevo-3100 imaging system to
analyze systolic and diastolic function, respectively. Cardiac function in hrAnxA1
treatment studies was assessed blindly. Details are available in SI Appendix.
Assessment of Arthritic Scores. Disease was monitored by assessing the clinical
score as described previously (14). Arthritic scores in hrAnxA1 treatment
studies were assessed blindly. Details are available in SI Appendix.
Quantification of Cardiomyocyte Size and Collagen Deposition. Diameters of
cardiomyocytes were measured using hematoxylin–eosin sections. Collagen
deposition was determined using Sirius red-stained sections as detailed in SI
Appendix. Cardiomyocyte size and collagen deposition in hrAnxA1 treat-
ment study were assessed blindly.
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Flow Cytometry. Flow cytometry of heart tissue was performed as detailed in
SI Appendix. All flow cytometry analyses were carried out blindly.
RT-PCR RNA Quantification. The mRNA expression of exemplar proin-
flammatory, proresolving, fibrosis, and hypertrophy markers were deter-
mined in whole mouse heart or kidney tissue. All RT-PCR analyses were
conducted blindly. Details are available in SI Appendix.
Statistics. All values described in the text and figures are presented as mean ±
SEM or mean values of n observations. One-way ANOVA followed by Bon-
ferroni’s post hoc test or unpaired Student’s t test were used to compare
intergroup differences. Two-way ANOVA followed by Bonferroni’s post hoc
test was used to compare time-courses. In all cases, a P < 0.05 was considered
statistically significant.
Data Availability. All study data are included in the article and/or supporting
information.
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